Cargando…

Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide, and its incidence is rising. HCC develops almost exclusively on the background of chronic liver inflammation, which can be caused by chronic alcohol consumption, viral hepatitis, or an unhealthy diet....

Descripción completa

Detalles Bibliográficos
Autores principales:	Mroweh, Mariam, Roth, Gaël, Decaens, Thomas, Marche, Patrice N., Lerat, Hervé, Macek Jílková, Zuzana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917860/ https://www.ncbi.nlm.nih.gov/pubmed/33670268 http://dx.doi.org/10.3390/ijms22041794

Ejemplares similares

Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma
por: Mroweh, Mariam, et al.
Publicado: (2020)

Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model
por: Kurma, Keerthi, et al.
Publicado: (2022)

Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
por: Jilkova, Zuzana Macek, et al.
Publicado: (2018)

Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma
por: Dumolard, Lucile, et al.
Publicado: (2020)

DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma
por: Kurma, Keerthi, et al.
Publicado: (2021)

Sex Differences in Spontaneous Degranulation Activity of Intrahepatic Natural Killer Cells during Chronic Hepatitis B: Association with Estradiol Levels
por: Macek Jilkova, Zuzana, et al.
Publicado: (2017)

Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Chronic Intermittent Hypoxia Increases Cell Proliferation in Hepatocellular Carcinoma
por: Carreres, Lydie, et al.
Publicado: (2022)

Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C
por: Malov, S.I., et al.
Publicado: (2021)

Reply to Comment on “Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554
por: Macek Jilkova, Zuzana, et al.
Publicado: (2020)

Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals
por: Macek Jílková, Zuzana, et al.
Publicado: (2020)

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation
por: Dumolard, Lucile, et al.
Publicado: (2023)

Gamma delta T cells in hepatocellular carcinoma: Sunrise of new therapy based on Vδ2 T cells?
por: Macek Jilkova, Zuzana
Publicado: (2022)

Increased Intrahepatic Expression of Immune Checkpoint Molecules in Autoimmune Liver Disease
por: Macek Jilkova, Zuzana, et al.
Publicado: (2021)

Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line
por: Roth, Gael S., et al.
Publicado: (2020)

Functions of Liver Natural Killer Cells Are Dependent on the Severity of Liver Inflammation and Fibrosis in Chronic Hepatitis C
por: Fugier, Emilie, et al.
Publicado: (2014)

Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
por: Roth, Gaël Stéphane, et al.
Publicado: (2020)

GNS561, a New Autophagy Inhibitor Active against Cancer Stem Cells in Hepatocellular Carcinoma and Hepatic Metastasis from Colorectal Cancer
por: Brun, Sonia, et al.
Publicado: (2021)

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions
por: Brun, Sonia, et al.
Publicado: (2021)

The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy
por: Guizhen, Zhang, et al.
Publicado: (2022)

Role of DTL in Hepatocellular Carcinoma and Its Impact on the Tumor Microenvironment
por: Li, Zuyin, et al.
Publicado: (2022)

Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma
por: Roth, Gael S., et al.
Publicado: (2022)

Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization
por: Roth, Gael, et al.
Publicado: (2022)

Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment
por: Mukai, Shohei, et al.
Publicado: (2021)

Bioinformatics Analysis of Prognostic Tumor Microenvironment-Related Genes in the Tumor Microenvironment of Hepatocellular Carcinoma
por: Tian, Zongbiao, et al.
Publicado: (2020)

The Chicken Embryo Model: A Novel and Relevant Model for Immune-Based Studies
por: Garcia, Paul, et al.
Publicado: (2021)

The Mechanism Underlying the ncRNA Dysregulation Pattern in Hepatocellular Carcinoma and Its Tumor Microenvironment
por: Xue, Chen, et al.
Publicado: (2022)

Role of Periostin in Hepatocellular Carcinoma: The Importance of Tumor Microenvironment
por: Lee, Jung Il
Publicado: (2016)

Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma
por: Xiang, Shixin, et al.
Publicado: (2021)

Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment
por: Wang, Haiqiang, et al.
Publicado: (2022)

Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
por: Feng, Hai, et al.
Publicado: (2022)

Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
por: Chen, Chen, et al.
Publicado: (2023)

Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma
por: Li, Zishuai, et al.
Publicado: (2023)

The role of noncoding RNAs in the tumor microenvironment of hepatocellular carcinoma: Noncoding RNAs in the tumor microenvironment of HCC
por: Yang, Qianqian, et al.
Publicado: (2023)

pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma
por: Kuchuk, Olga, et al.
Publicado: (2018)

Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis
por: Roth, Gaël S., et al.
Publicado: (2021)

Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy
por: Tahmasebi Birgani, Maryam, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gl9529mjoff4lvq04ja804dkri